<DOC>
	<DOCNO>NCT01308840</DOCNO>
	<brief_summary>The purpose study determine disease response GEMOX-Panitumumab ( GEMOX-P ) KRAS/ BRAF wild-type , Stage IV , biliary tract gallbladder cancer patient previously receive chemotherapy . This study also examine potential toxicity , progression-free overall survival population .</brief_summary>
	<brief_title>Gemcitabine , Oxaliplatin Panitumumab Kras/B-raf Wild-Type Biliary Track Gallbladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm metastatic unresectable Kras Braf wildtype biliary tract adenocarcinoma ( bile duct , hepatic duct , cystic duct , common bile duct , ampulla Vater gallbladder adenocarcinoma ) . Screening tumor Kras Braf mutation require formalin fix paraffin embed tumor block core needle excisional biopsy . Participants must measurable disease . No prior chemotherapy biliary tract gallbladder cancer . Prior chemoembolization radiation liver allow long measurable disease outside chemoembolization radiation area baseline characteristic meet least 4 week lapse since therapy . No prior gemcitabine oxaliplatin antiEGFR therapy include panitumumab therapy allow . Age minimum 18 year old . Life expectancy great 3 month . ECOG performance status &lt; 1 Participants must normal organ marrow function define : Leukocytes &gt; 3,000/mcL Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL hemoglobin &gt; 9mg/dL Mg &gt; 1.2 mEq/L total bilirubin &lt; 2.5 mg/dL AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal ( unless liver involved tumor , case transaminase must 5 x upper limit normal ) , creatinine within normal institutional limit creatinine clearance &gt; 60 mL/min/1.73 m2 subject creatinine level institutional normal Patients concurrent malignancy may include disease characterize one follow definition : 1 . Malignancy treat curative intent know active disease present 3 year prior randomization felt low risk recurrence treat physician . 2 . Adequately treat nonmelanomatous skin cancer lentigo maligna without evidence disease . 3 . Adequately treated cervical carcinoma situ without evidence disease . 4 . Prostatic intraepithelial neoplasia without evidence prostate cancer . 5 . DCIS without evidence breast cancer . Ability understand willingness sign write informed consent document . Patients may prior placement stent shunt relieve biliary obstruction . Participants chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier . Participants may receive study agent . Participants know brain metastasis . History allergic reaction attribute compound similar chemical biologic composition gemcitabine , oxaliplatin panitumumab . Patients preexist peripheral neuropathy grade 2 great severity accord Common Terminology Criteria NCI ( version 3.0 ) ineligible . Patients biliary obstruction inadequate drainage total bilirubin &gt; 2.5 mg/dL ineligible . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement , History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . Known positive test ( ) HIV , hepatitis C virus , acute chronic active hepatitis B infection . Pregnant woman exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Unresectable</keyword>
	<keyword>metastatic</keyword>
	<keyword>biliary tract</keyword>
	<keyword>gallbladder cancer</keyword>
</DOC>